Abstract
Cancer-associated fibroblasts (CAFs), the most abundant cells in the tumor microenvironment, play an indispensable role in cancer initiation, progression, metastasis, and metabolism. The limitations of traditional treatments can be partly attributed to the lack of understanding of the role of the tumor stroma. For this reason, CAF targeting is gradually gaining attention, and many studies are trying to overcome the limitations of tumor treatment with CAF as a breakthrough. Glutamine (GLN) has been called a "nitrogen reservoir" for cancer cells because of its role in supporting anabolic processes such as fuel proliferation and nucleotide synthesis, but ammonia is a byproduct of the metabolism of GLN and other nitrogenous compounds. Moreover, in some studies, GLN has been reported as a fundamental nitrogen source that can support tumor biomass. In this review, we discuss the latest findings on the role of GLN and ammonia in the crosstalk between CAFs and cancer cells as well as the potential therapeutic implications of nitrogen metabolism.
Introduction: The Tumor Microenvironment and CAFs
Traditional cancer research has long focused on the "seed" (the cancer cell) while often ignoring the "soil" (the tumor microenvironment or TME). However, many treatments fail because the surrounding stroma—dominated by cancer-associated fibroblasts (CAFs)—provides a metabolic sanctuary for cancer cells. CAFs are not a monolithic population; they originate from various cell types, including resident fibroblasts, mesenchymal stem cells, and even epithelial cells through transition processes.
Once activated, CAFs drive tumor progression through multiple channels: secreting growth factors, remodeling the extracellular matrix, and, crucially, engaging in metabolic "handshakes" with cancer cells.
Metabolic Crosstalk: Glutamine and Ammonia
Cancer cells are notoriously "addicted" to glutamine (GLN) for nitrogen and energy. While they consume vast amounts of GLN, they produce ammonia ($NH_3$) as a byproduct. Long viewed simply as a toxic waste product, ammonia is now recognized as a critical signaling molecule and recycled nitrogen source that supports tumor biomass production.
The metabolic relationship between CAFs and cancer cells is symbiotic. In nutrient-poor environments, CAFs act as metabolic factories. They can recycle ammonia and lactic acid—byproducts of cancer cell metabolism—to resynthesize glutamine, which is then secreted back into the TME to feed the "addicted" cancer cells.
Key Molecular Drivers
The review synthesizes findings on several key regulatory mechanisms:
- Oncogenic Regulation: Genes like MYC and mTOR upregulate glutamine transporters (e.g., SLC1A5) and enzymes like glutaminase (GLS).
- Exosomal Signaling: Cancer cells can "reprogram" fibroblasts by sending exosomes containing microRNAs (like miR-105), which activate MYC in the stroma, turning fibroblasts into efficient nutrient recyclers.
- The "Reverse Warburg" Effect: Cancer cells induce autophagy and senescence in CAFs, forcing them to "digest" their own organelles to release glutamine and other metabolites into the extracellular space.
Clinical Implications and Challenges
Despite the clear importance of these pathways, clinical translation has been difficult.
- Transporter Overexpression: SLC1A5 is consistently overexpressed in solid tumors (colon, lung, prostate), making it a primary target for "starvation" therapies.
- Single-Target Failure: Many glutaminase (GLS) inhibitors, such as CB-839 (Telaglenastat), have shown promise in preclinical models but have stalled in clinical trials. A major reason for this is the compensatory role of CAFs; when cancer cell glutamine metabolism is blocked, CAFs increase their synthesis to fill the gap.
- Dual-Targeting Strategy: Emerging evidence suggests that combining GLS inhibitors (targeting cancer cells) with GLUL inhibitors (targeting glutamine synthesis in CAFs) is significantly more effective than monotherapy.
Limitations and Future Directions
Current research is limited by the use of 2D co-cultures and mouse models that do not fully replicate the human TME's complexity, including varying oxygen levels and immune cell interactions. Furthermore, systemic inhibition of glutamine metabolism poses risks of neurotoxicity and gastrointestinal distress, as GLN is essential for healthy tissues.
Future research must focus on "dual-targeting" strategies and utilize mathematical modeling to predict how these complex metabolic circuits will respond to disruption, ultimately aiming for more precise and less toxic therapeutic interventions.
Summary updated